<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02380755</url>
  </required_header>
  <id_info>
    <org_study_id>385.615</org_study_id>
    <secondary_id>2013/16781-1</secondary_id>
    <nct_id>NCT02380755</nct_id>
  </id_info>
  <brief_title>Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism</brief_title>
  <official_title>Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypogonadism is a clinical condition that can be associated with obesity in man. Controversy
      exists regarding if its a condition that needs to be treated. The standard Testosterone
      Therapy is associated with increase in cardiovascular risks, according to some studies, and
      leads to infertility. The use of Clomiphene Citrate in this sub population of obese man as an
      alternative treatment option is not well studied. The aim of this protocol is to evaluate the
      cardiovascular risks, metabolic and hormonal parameters in a double blinded randomized
      placebo trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypogonadism (low testosterone level) in obese man is a clinical condition which treatment is
      controversial. Most of this controversy remains regarding the association between
      cardiovascular risk elevation and Testosterone replacement therapy in some studies.

      This protocol is a double blinded randomized placebo trial and 2 groups will be followed. The
      primary end-point of this research is the correlation between the serum testosterone and
      flow-mediated dilatation of the brachial artery (FMDAB), circulating levels of sICAM-1,
      sVCAM-1, E-selectin and progenitor endothelial cells.

      The secondary end-points include:

      (1) the evaluation of metabolic parameters: weight, abdominal circumference, glycaemia, total
      cholesterol, fractions and triglycerides, homeostasis model assessment index (HOMA) and
      bioelectrical impedance parameters; and (2) hormonal parameters: total testosterone levels,
      sex hormone-binding globulin (SHBG), Luteinizing Hormone (LH) , Follicle stimulating hormone
      (FSH) and Estradiol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>78 patients were randomized (1:1) to receive Clomiphene Citrate (CC) 50 mg during 12 weeks or placebo (PLB). MAIN OUTCOME MEASURES: flow-mediated dilatation of the brachial artery (FMDAB), circulating levels of sICAM-1, sVCAM-1, E-selectin and progenitor endothelial cells. Secondary endpoints: Body mass index (BMI), abdominal circumference (AC), glycaemia, total cholesterol, fractions and triglycerides, HOMA-IR index, bioelectrical impedance parameters, Adam questionnaire and hormonal parameters (total testosterone levels, SHBG, LH, FSH and Estradiol).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>randomized, double blinded, placebo-controlled, parallel group, single-center study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>baseline up to 12 weeks</time_frame>
    <description>Flow-mediated dilatation of the brachial artery (FMDAB): Brachial artery FMD is calculated as the percentage increase in brachial artery diameter with hyperemia induced relative to the resting brachial artery diameter. Percentage of brachial artery diameter is measured as FMD diameter/basal diameter.
Icam, vcam and selectin
Endothelial progenitor cels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Testosterone</measure>
    <time_frame>baseline up to 12 weeks</time_frame>
    <description>electrochemical luminescence analysis in blood sample</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Obesity</condition>
  <condition>Hypoandrogenism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One pill every other day during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomiphene Citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clomiphene citrate 50 mg orally daily (Serophene) during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>50 mg orally daily during 12 weeks</description>
    <arm_group_label>Clomiphene Citrate</arm_group_label>
    <other_name>Serophene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill orally daily during 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ADAM questionnaire positive for 3 or more questions

          -  Total serum Testosterone lower than 300 ng/dL in two different occasions, within a
             1-week minimum interval. This blood sample must be collected between 8 and 11 a.m.

          -  Low or Inappropriate normal serum Luteinizing hormone (LH) level

          -  ATP III Metabolic Syndrome Criteria

          -  Obesity - BMI over 30 kg/m2

        Exclusion Criteria:

          -  Systemic illness, such Rheumatoid Arthritis, Cushing disease, liver insufficiency or
             renal insufficiency. -Use of certain medications (opiates, high-dose glucocorticoid
             therapy, methadone)

          -  Eating disorders

          -  Testicular volume below 4 mL

          -  Use of recreational drugs

          -  Excessive exercise practice

          -  Men in treatment for prostatic cancer

          -  Hyperprolactinaemia

          -  Hemochromatosis

          -  History of headache

          -  Systolic blood pressure lower than 100 mmHg

          -  Previous adverse reactions to nitrate compounds

          -  Diabetes over 10 years of diagnosis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cintia Cercato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital das Clínicas da Faculdade de Medicina da USP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elaine Maria F Costa, Prof, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina da USP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prédio dos ambulatórios HCFMUSP - PAMB</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2015</study_first_submitted>
  <study_first_submitted_qc>March 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2015</study_first_posted>
  <last_update_submitted>December 23, 2017</last_update_submitted>
  <last_update_submitted_qc>December 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Cintia Cercato</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Flow-mediated dilatation</keyword>
  <keyword>Clomiphene citrate</keyword>
  <keyword>sICAM-1</keyword>
  <keyword>sVCAM-1</keyword>
  <keyword>sE- Selectin</keyword>
  <keyword>Endothelial function</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Selective Estrogen Receptor Modulators</keyword>
  <keyword>Estrogen Receptor Modulators</keyword>
  <keyword>Infertility, Male</keyword>
  <keyword>Endothelial Progenitor Cells</keyword>
  <keyword>Obesity</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
    <mesh_term>Selective Estrogen Receptor Modulators</mesh_term>
    <mesh_term>Estrogen Receptor Modulators</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

